https://kalkinemedia.com/news/prnews/innovent-dosed-first-participant-in-phase-3-clinical-study-neoshot-of-ibi310-anti-ctla-4-monoclonal-antibody-in-combination-with-sintilimab-for-msi-hdmmr-colon-cancer-neoadjuvant-therapy